Free Trial

Alexandria Hammond Analyst Performance

Analyst at Bank of America

Alexandria Hammond is a stock analyst at Bank of America in the medical sector, covering 7 publicly traded companies. Over the past year, Alexandria Hammond has issued 10 stock ratings, including buy, hold, and sell recommendations. While full access to Alexandria Hammond's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Alexandria Hammond's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
11 Last 1 Years
Buy Recommendations
72.73% 8 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy72.7%8 ratings
Hold18.2%2 ratings
Sell9.1%1 ratings

Out of 11 total stock ratings issued by Alexandria Hammond at Bank of America, the majority (72.7%) have been Buy recommendations, followed by 18.2% Hold and 9.1% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
57.1% of companies on NASDAQ
4 companies
NYSE
42.9% of companies on NYSE
3 companies

Alexandria Hammond, an analyst at Bank of America, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Alexandria Hammond of Bank of America specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
3 companies
42.9%
MED - BIOMED/GENE
3 companies
42.9%
MED - DRUGS
1 company
14.3%

Alexandria Hammond's Ratings History at Bank of America

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
5/4/2026Reiterated Rating$965.77$1,325.00Outperform
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2/20/2026Lower Price Target$436.87$529.00Neutral
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/12/2026Boost Price Target$155.80$170.00Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1/28/2026Boost Price Target$139.72$155.00Outperform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1/8/2026Upgrade$108.52$135.00Outperform
Pfizer Inc. stock logo
PFE
Pfizer
12/17/2025Set Price Target$25.56$24.00Underperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
12/15/2025Reiterated Rating$120.40$150.00Outperform
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
11/3/2025Upgrade$418.90$445.00Neutral
89BIO stock logo
ETNB
89BIO
8/25/2025Lower Price Target$9.39$29.00Buy
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
5/27/2025Boost Price Target$49.12$64.00Buy
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
1/30/2025Upgrade$54.00$63.00Buy